Biomedical subjects

M A Ariano

Publications and source records attributed to M A Ariano.

At least 37 records · Page 2Linked to original sources

PubMed1994

Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes.

Anti-peptide antibodies were generated against amino acid sequences of intracellular and extracellular portions of the native proteins for the cloned rat D1A and D3 dopamine receptor subtypes in order to determine the cellular distribution of these specific forms in the brain. These polyclonal antisera exhibited high specific titers, assessed by ELISA and immunofluorescent detection of functional recombinant receptor proteins expressed in stably transfected Chinese hamster ovary (CHO) cells. Central nervous system (CNS) areas of the male rat were examined using standard immunofluorescent methods in fresh frozen tissues. This paradigm detected D1A-like and D3-like dopamine receptor staining primarily in larger-sized neurons throughout layers 3 and 5 of the cortex, in medium-diameter somata of the striatum, and in the densely packed cells of the olfactory tubercle and hippocampal formation. More attenuated immunoreactivity for both dopamine receptor subtypes was noted in the substantia nigra, not associated with perikarya. Differences in cellular staining patterns and intensity were evident between the D1A-like and D3-like dopamine receptor subtypes. Equivalent morphological elements exhibited dopamine receptor expression following incubation using antisera generated against either extracellular or intracellular epitopes of either the D1A or D3 native proteins. Dopamine receptor immunoreactivity could not be detected in the cerebellum at equivalent antisera dilutions used to discriminate cellular staining patterns within the forebrain. Fluorescent-labeled latex microspheres were infused into the substantia nigra terminal fields to retrogradely identify the cell bodies of the striatonigral projection system. This paradigm showed that 80% of striatonigral neurons expressed D1A-like receptors, while 65% demonstrated D3-like dopamine receptor staining. This distribution for the D1A-like and D3-like receptor subtypes suggests that overlap may occur in the expression of the receptors in the striatonigral neuron population. Our previous results localizing cellular D2-like receptor expression patterns in this projection system of the rat neostriatum implies that all three of these dopamine receptor subtypes may be co-expressed in this efferent system.

Amino Acid Sequence↗

PubMed1994

Dopamine receptor binding on identified striatonigral neurons.

Dopamine receptors have been divided into two families, known as D1 and D2, based on their ability to bind distinct ligands, and their use of separate post-synaptic transduction systems. Determining the specific cellular location for these dopamine receptors in the striatum is important to the design of drug treatments for disorders with suspected dopaminergic involvement such as Parkinson's disease. This study examined the binding of D1 and D2 antagonist ligands on identified striatonigral neurons using in vitro fluorescent techniques. The results indicate that striatonigral neurons express both pharmacological subfamilies of dopamine receptor binding sites.

Animals↗

PubMed1993

Localization of D2 dopamine receptors in vertebrate retinae with anti-peptide antibodies.

Dopamine plays an important role in modulating various aspects of retinal signal processing. The morphology of dopaminergic neurons and its physiological effects are well characterized. Two classes of receptor molecules (D1 and D2) were shown pharmacologically to mediate specific actions, with differences between individual groups of vertebrates. In an attempt to better understand dopaminergic mechanisms at the cellular level, we used antisera against D2 receptors and investigated the localization of the dopamine D2 receptor in the retinae of rat, rabbit, cow, chick, turtle, frog, and two fish species with immunofluorescence techniques. Antisera were raised in rabbits to two oligopeptides predicted from rat D2 receptor cDNA; one specific for the splice-variant insertion in the third cytoplasmic loop and the other directed towards the extracellular amino terminal region shared by both short and long isoforms. Preadsorption with the synthetic peptide resulted in a significant reduction of label, indicating the presence of specific binding in all species except turtle and goldfish. The pattern of labelling produced by the two antisera was essentially identical; however, the staining obtained with antiserum to the extracellular motif was always more intense. Specific staining was present in photoreceptor inner and outer segments, and in the outer and inner plexiform layers of all species. In mammals and chick, strongly fluorescent perikarya were observed in the ganglion cell layer and at the proximal margin of the inner nuclear layer. Label may be present in the pigment epithelium but could not be established beyond doubt. This pattern of labelling is in accordance with previous observations on D2 receptor localization by means of radioactive ligand binding and in situ hybridization techniques. It suggests that retinal dopamine acts as a neuromodulator as well as a transmitter. In the distal retina, it may reach its targets via diffusion over considerable distances, even crossing the outer limiting membrane; in the inner and outer plexiform layers, conventional synaptic transmission seems to coexist with paracrine addressing of more distant targets, and D2 receptors are expressed by both amacrine and ganglion cells.

Amphibians↗

PubMed1993

D2 dopamine receptor distribution in the rodent CNS using anti-peptide antisera.

D2 dopamine receptors were identified immunohistochemically in rodent tissues using anti-peptide antisera to distinguish regional and cellular staining patterns. These subtype selective polyclonal antibodies were directed against both extracellular and intracellular regions of the native protein and showed that the D2 dopamine receptors are widely distributed within the nervous system. The highest expression of D2-like dopamine receptor immunoreactivity was visualized in the forebrain and components of the basal ganglia, supportive of previous investigations of the D2 dopamine receptor distribution using in vitro autoradiographic ligand binding or in situ hybridization for its messenger RNA. The anti-peptide antisera could detect the dopamine receptor in both perfusion-fixed and fresh-frozen tissue preparations. The reactive cells and their processes could be distinguished using experimental incubations from 1:8,000 (in immunofluorescence processing) to 1:80,000 (in immunoperoxidase processing) in the most reactive nervous system region, the neostriatum. The antisera are selectively directed against extracellular or intracellular epitopes in both the long and short isoforms of the D2 dopamine receptor, and should prove useful in subsequent studies of the subcellular distribution of this receptor in particular, and the dopamine system in general.

Amino Acid Sequence↗

PubMed1993

Are neostriatal dopamine receptors co-localized?

The postsynaptic effects of dopamine in the neostriatum are mediated by five G-protein-coupled receptors. The extent to which these receptors are co-localized in neostriatal neurons has become controversial. This debate has far-reaching implications for treatment strategies in disorders of dopaminergic signaling, such as Parkinson's disease and schizophrenia. This review examines the molecular and cellular evidence for and against co-localization, including new information derived from single-cell mRNA amplification and patch-clamping of isolated neurons. It is concluded that this evidence is largely consistent with co-localization of functionally significant receptors of the D1 and D2 families in the majority of neostriatal efferent neurons. This conclusion has important implications for parallel processing models of the neostriatum.

Animals↗

PubMed1992

D2 dopamine receptor localization on striatonigral neurons.

Two major pharmacological classes of dopamine receptors exist in the central nervous system. These receptors have been designated as D1 or D2 based upon their differing pharmacology and influence on the cyclic AMP second messenger system. Different genes for the D1 and D2 dopamine receptors have been isolated and are found to be expressed in high abundance. Within the neostriatum, however the cellular distribution of the dopamine receptors is equivocal. Dopamine receptors are the targets for drugs used to treat neurological dysfunctions such as Parkinson's disease and schizophrenia, and thus knowledge of their specific cellular location is important for devising future therapeutic manipulations. Using retrograde labeling methods combined with immunofluorescence of various receptor amino acid sequences, this study has examined the postsynaptic distribution of striatal D2 dopamine receptors. We have found that the D2 dopamine receptor can be visualized on a minimum of 60% of the neurons projecting from the neostriatum to the substantia nigra. However, some 65% of all D2 receptor positive cells are represented by other intrinsic neurons of this basal ganglia nucleus.

Amino Acid Sequence↗

PubMed1991

Multiple fluorescent ligands for dopamine receptors. I. Pharmacological characterization and receptor selectivity.

We report the synthesis and pharmacological characterization of novel fluorescently labeled ligands with high affinity and specificity for D1 and D2 dopamine receptors. D1-selective antagonist probes have been synthesized using (R,S)-5-(4'-aminophenyl)-8-chloro-2,3,4,5-tetrahydro-3-methyl-[1H]-3- benzazepin-7-ol, the 4'-amino derivative of the high affinity D1-selective antagonist, SCH-23390, while D2-selective antagonist probes were synthesized using the high affinity, D2-selective agonist, N-(p-aminophenethyl)spiperone (NAPS). In addition, we have synthesized fluorescent probes using an amino-derivative of the high affinity, D2-selective agonist, 2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin (PPHT or N-0434). These ligands were coupled to the fluorescent moieties, fluorescein, rhodamine, coumarin, Texas red, Cascade blue, or Bodipy. This resulted in a wide variety of dopaminergic ligands which fluoresce at different wavelengths: Cascade blue and coumarin are blue fluorophores, fluorescein and Bodipy, are yellow-green, and Texas red and rhodamine are red. The interaction of these fluorescent ligands with dopamine and serotonin receptors was evaluated by examining their ability to compete for radioligand binding to D1 and D2 dopamine receptors and 5-HT1A, 5-HT1C and 5-HT2 serotonin receptors. We report here that these novel fluorescent ligands exhibit high affinity and, in general, selectivity for either D1 or D2 dopamine receptors. In addition, we demonstrate that the fluorescent derivatives of PPHT retain the full agonist efficacy exhibited by the parent compound.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenylyl Cyclases↗

PubMed1991

Multiple fluorescent ligands for dopamine receptors. II. Visualization in neural tissues.

Selective dopamine receptor ligands, (R,S)-5-(4'-aminophenyl)-8-chloro-2,3,4, 5-tetrahydro-3-methyl-[1H]-3-benzazepin-7-ol, the 4'-amino derivative of the high affinity D1 receptor antagonist SCH 23390, the high affinity D2 receptor antagonist N-(p-aminophenethyl)-spiperone or NAPS, and the D2 selective agonist, 2-(N-phenethyl-N-propyl)-amino-5-hydroxytetralin or PPHT were chemically coupled to the fluorescent compounds, Bodipy, Cascade blue, coumarin, fluorescein, rhodamine, or Texas red. The utility of the 6 fluorescent moieties linked to the 3 dopamine receptor binding ligands for anatomical study of regional and cellular distribution patterns of the two dopaminergic receptor subtypes has been assessed in frozen sections of the rat striatum and compared to our previous report using the rhodamine-labeled antagonists. The regional staining for the two dopaminergic receptor binding sites supports previous work using in vitro receptor autoradiographic analyses; the D1 receptor binding was more robust than that of D2 receptors in the caudate nucleus. The cellular element which most frequently expressed striatal D1 binding sites had a medium-diameter cell body. Medium-sized cells also exhibited fluorescence for the D2 binding site, as did a much larger diameter element; potentially the cholinergic interneuron of the caudate nucleus. The pharmacological specificity for each of the different D1 fluorescent antagonist ligands in the tissues was determined by competition with 100-fold excess of unlabeled SCH 23390 (non-specific binding), spiroperidol (binding selectivity), the stereoactive paired isomers of butaclamol, and the serotonin 5-HT2 receptor antagonist ketanserin. The same criteria were used to assess the different D2 fluorescent agonist and antagonist ligand derivatives. The anatomical efficacy of these novel ligands was determined using selective dichroic filters to stimulate the fluorescent moieties in the optimal excitation wavelength, and the amount of fluorescent dopamine receptor binding was photographically measured and contrasted for each of the newly synthesized fluoroprobes. Using the most pharmacologically specific and anatomically efficient of these novel fluoroprobes, we determined the localization pattern of the D1 and D2 dopamine receptor binding sites in tissues reported to exhibit both subtypes of the receptor. The cellular distribution of the dopamine receptor binding sites was determined concurrently using fluoroprobes in the forebrain, mesencephalon, pituitary, retina, and superior cervical ganglion of the rodent, and bovine adrenal medullary chromaffin cells were examined using the rhodamine-labeled antagonists.

Adrenal Medulla↗

PubMed1991

Characterization of anti-peptide antibodies for the localization of D2 dopamine receptors in rat striatum.

Seven different peptides of 14-23 residues in length based on the predicted amino acid sequence of the cloned rat D2 receptor cDNA were used as immunogens to develop antibodies in rabbits. Two of these peptides were derived from the amino terminus and four were from the third cytoplasmic loop, including one to the splice variant insertion sequence and one to the carboxyl terminus of the receptor protein. These peptides were conjugated to bovine thyroglobulin prior to rabbit immunization. Antibody production was monitored by a solid-phase ELISA. With the exception of the carboxyl-terminal peptide, all of the peptide immunogens produced antiserum of high titer ranging from 1:10(4) to 1:10(6) on ELISA. Specificity of the reaction was demonstrated by the absence of a response in the preimmune serum and by the absence of cross-reactivity between the various antisera and the nonimmunization peptides. Moreover, preincubation of the antiserum with the immunization peptide, but not other peptides, blocked the subsequent ELISA reactions. Some of the antisera were additionally characterized by immunodot assays using solubilized rat striatal membranes blotted onto nitrocellulose. Positive reactions with antiserum dilutions of 1:500 were observed that were dependent on the presence and concentration of membrane protein and were not observed using preimmune serum. Additionally, immunofluorescent staining by the D2 receptor antiserum was observed on cells that had been transfected with the D2 receptor cDNA but not on untransfected cells. Immunoprecipitation of the photoaffinity-labelled and solubilized D2 receptor also suggested that the antisera were able to directly recognize the native receptor protein. Immunohistochemical localization of the D2 receptor in slices of fresh frozen and perfusion-fixed rat brain was performed using these antisera. Within the striatum, about 50% of the medium-sized neurons were labeled as well as large, putatively cholinergic interneurons.

Amino Acid Sequence↗

PubMed1991

Striatal D1 dopamine receptor morphochemistry following continuous or intermittent L-dopa replacement therapy.

Striatal dopamine deafferentation has previously been found to diminish D1 dopamine receptor clustering in association with striatal cyclic AMP-immunoreactive neurons. The administration of the dopamine precursor levodopa (L-DOPA) to animals with unilaterally placed 6-hydroxydopamine nigrostriatal tract lesions now appears to partially restore D1 dopamine receptor morphochemical organization in the deafferented striatum. Differences in the mode of levodopa delivery produced dissimilar D1 recovery patterns. The prodrug, L-DOPA methyl ester, was administered in combination with the peripheral aromatic amino acid decarboxylase inhibitor, benserazide, to achieve consistent plasma levels of the dopamine precursor. Continuous levodopa infusion (100 mg/kg/day, ip) led to a slight dorsomedial reassociation of D1 receptor binding sites with the postsynaptic cyclic AMP transduction system on the deafferented side. In contrast, intermittent levodopa therapy (50 mg/kg, ip, bid) produced a noticeable down regulation of the dopamine receptor system and also contributed to some region-specific recovery of the morphochemical pattern of D1 receptor binding site reaggregation with the postsynaptic cyclic AMP second messenger transduction system. These results suggest that exogenous levodopa replacement therapy desensitizes striatal D1 dopamine receptors. This was substantiated using image analysis of densitometric histograms. The down regulation of D1 receptors is dependent on the levodopa treatment regimen employed. Our findings provide a potential morphological basis for the behavioral desensitization shown previously in response to chronic, intermittent levodopa administration.

Animals↗

PubMed1990

Activation of facilitation calcium channels in chromaffin cells by D1 dopamine receptors through a cAMP/protein kinase A-dependent mechanism.

Facilitation calcium channels in unstimulated bovine chromaffin cells are normally quiescent but are activated by large pre-depolarizations or by repetitive depolarization in the physiological range. The activation of these 27-pS dihydropyridine-sensitive channels by repetitive stimulation, such as by increased splanchnic nerve activity, can lead to an almost twofold increase in Ca2+ current in these cells. This increase in Ca2+ current is of probable physiological importance in stimulating rapid catecholamine secretion in response to danger or stress. We have identified D1 dopaminergic receptors on bovine chromaffin cells by fluorescence microscopy. Here we show that stimulation of the D1 receptors activates the facilitation Ca2+ currents in the absence of pre-depolarizations or repetitive activity, and that activation by D1 agonists is mediated by cyclic AMP and protein kinase A. The recruitment of facilitation Ca2+ channels by dopamine may form the basis of a positive feedback loop mechanism for catecholamine secretion.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗

PubMed1989

Striatal muscarinic receptors are associated with substance P and somatostatin containing neurons.

The cellular localization of muscarinic acetylcholine binding sites (mAChr) in relation to immunohistochemically characterized cell populations within the rat caudate nucleus has been determined using in vitro autoradiography of the reversible antagonist ligand, quinuclidinyl benzilate [( 3H]QNB). The pattern of autoradiographic silver grain deposition in the striatum was contrasted with the localization of two peptide-containing neuronal populations in the striatum. Substance P-immunoreactive somata demonstrated prevalent association of mAChr binding sites, as did somatostatin-immunoreactive cells. Substantially more striatal muscarinic binding sites were aggregated over the somatostatin interneuron population of the caudate nucleus than were associated with the substance P somata in concurrently performed experiments. This data further substantiates the heterogeneity in organization of the caudate nucleus, and the results are discussed in relation to the processing of information within this basal ganglia region.

Animals↗

PubMed1989

Long-term changes in striatal D1 dopamine receptor distribution after dopaminergic deafferentation.

The morphochemical disposition of the adenylate cyclase-linked dopamine receptor (D1 type) in the rat striatum has been assessed at various time points after a neurotoxic lesion of the dopaminergic afferent pathway to the caudate nucleus. D1 receptor binding sites in the caudate nucleus were determined by in vitro autoradiography of the substituted benzazepine D1 antagonists, [3H]SCH 23390 or [125I]SCH 23982, and contrasted to the pattern of striatal immunohistochemical reactivity of the second messenger compound, cyclic 3',5'-adenosine monophosphate. The results demonstrate that the specific association of this dopamine receptor type with cyclic 3',5'-adenosine monophosphate-stained neurons is abolished at 7 days following chemical interruption of the nigrostriatal pathway, and the receptor disruption is persistent for durations as long as 20 weeks. This investigation suggests that once the postsynaptic receptor pathology is produced by deafferentation, it does not recover the selective morphochemical relationship normally established with the target cell containing the second messenger. This is in contrast to modest biochemical recuperation in D1 dopamine receptor binding seen using this experimental paradigm. This change in D1 dopamine receptor morphochemistry is discussed in relation to the neurochemical deficits produced by dopaminergic denervation and in Parkinson's disease.

Animals↗

PubMed1989

Direct visualization and cellular localization of D1 and D2 dopamine receptors in rat forebrain by use of fluorescent ligands.

The regional and cellular localization of the two subtypes of dopamine receptors, D1 and D2, have been ascertained in rat forebrain by use of fluorescent dopaminergic antagonist ligands. (R,S)-5-(4'-aminophenyl)-8-chloro-2,3,4,5-tetrahydro-3- methyl-[1H]-3-benzazepin-7-ol, the 4'-amino derivative of the high-affinity D1-specific antagonist SCH 23390, and the D2 selective antagonist N-(p-aminophenethyl)spiperone were chemically derivatized using the fluorescent compound tetramethylrhodamine. The modification of these antagonist ligands has allowed the specific, cellular resolution of the D1 and D2 receptor binding sites in intact, highly organized regions of forebrain slices in a very rapid experimental time frame. The regional localization of receptors labeled by the fluorescent probes is in agreement with previous receptor autoradiography studies. Moreover, the specific cellular binding patterns for both receptors can now be compared and contrasted to one another in the same tissue by using these fluorescent ligands. D1 receptor sites are most evident within the striatum and exhibit regions of intense "patch" fluorescence corresponding to receptor reactivity in cells and their processes. The distribution of D1 receptor binding is highly analogous to the pattern of dopamine terminal histofluorescence in the caudate nucleus. D2 receptor sites are less prevalent overall and may be localized to a subpopulation of the D1 fluorescent neurons in the caudate nucleus and nucleus accumbens regions.

Animals↗

PubMed1988

Striatal D1 dopamine receptor distribution following chemical lesion of the nigrostriatal pathway.

The morphochemical and biochemical distribution of the adenylate cyclase-linked dopamine receptor, or D1 subpopulation, has been examined in the rat striatum following a chemical lesion of the dopaminergic nigrostriatal pathway. The cellular pattern of D1 dopaminergic binding was assessed using in vitro autoradiographic localization of [3H]SCH 23390 or [125I]SCH 23982, selective D1 receptor antagonists, 1 week following unilateral infusion of the neurotoxin 6-hydroxydopamine (6-OHDA) into the substantia nigra. The specific association of the D1 binding sites with cyclic AMP-immunoreactive striatal neurons was abolished after lesion of the dopaminergic nigral afferents. The morphochemical disruption of the caudate D1 dopamine binding sites in relation to cyclic AMP-positive elements, a large proportion of which are striatonigral neurons, probably contributes to the dysfunctions in this subpopulation of dopamine receptor after depletion of the catecholamine neurotransmitter.

Animals↗

PubMed1987

Comparison of dopamine binding sites in the rat superior cervical ganglion and caudate nucleus.

A comparison of morphological and biochemical characteristics of the D1-type dopamine receptor has been assessed in two experimental tissues, the superior cervical ganglion (SCG) and caudate nucleus of the rat. Correlation of the distribution of this dopaminergic binding site using in vitro autoradiographic localization of [3H]SCH 23390, a selective D1-binding antagonist, demonstrated no specific association of this receptor subtype with cyclic AMP immunoreactive structures in the superior cervical ganglion. In contrast, the caudate nucleus demonstrated specific D1-binding sites associated with cyclic AMP immunoreactive elements. Biochemical analyses of the D1-dopamine binding sites showed only 20% of the amount of radioligand bound in SCG homogenates as compared to the quantity bound in homogenates of the caudate nucleus. The non-cyclase linked dopaminergic receptor, assessed using D2-type radioligand binding, was much less prevalent than the binding of the D1-subtype in either experimental tissue. Only a small amount of [3H]sulpiride binding, indicative of the D2-receptor subtype, could be measured in the SCG as compared to the caudate nucleus. This work has demonstrated differences in the amount, and the cellular association of dopamine binding sites in peripheral versus central nervous system areas with dopamine sensitive adenylate cyclase mechanisms.

Animals↗

PubMed1987

Neurochemical differences in the superior cervical ganglion of the spontaneously hypertensive rat stroke-prone variant.

The localization and distribution of catecholamines, selected neuropeptides, and the cyclic nucleotide second messengers has been determined in the superior cervical ganglion of the stroke-prone variant of the spontaneously hypertensive rat (SHR) and its normotensive Wistar-kyoto (WKY) control. Significant alteration in the frequency of occurrence of dopaminergic small intensely fluorescent cell clusters was seen in the stroke-prone variant of the SHR. The immunofluorescent localization of cyclic AMP (cAMP) and cyclic GMP (cGMP) were also changed in the stroke-prone variant, as was the immunofluorescent staining quantity of the neuropeptides somatostatin and substance P. The morphological pattern of staining for the various compounds in the normotensive control (WKY) was equivalent to the Sprague-Dawley rat strain. The implications of the altered neurochemistry in the superior cervical ganglion on the high blood pressure, and the predisposition for stroke in this strain are discussed.

Animals↗

PubMed1986

The immunofluorescence localization of glutamate decarboxylase in the rat superior cervical ganglion.

The immunofluorescence localization of glutamate decarboxylase (GAD, EC 4.1.1.15) has been determined in the superior cervical ganglion of the rat. Immunoreactivity was confined to clusters of small cells whose size is similar to that of the dopaminergic small intensely fluorescent (SIF) cells. In serial sections tested for GAD immunofluorescence and catecholamine histofluorescence there was no evidence of co-localization. These results suggest that a separate population of gamma-aminobutyric acid (GABA) synthesizing cells is present in the rat superior cervical ganglion.

Animals↗